Introduction
============

Although the prevalence of osteoporosis in men is lower than that in women,[@b1-cia-9-1247] male osteoporosis is still regarded as a tremendous health problem. Men with osteoporosis suffer from higher mortality after a fracture when compared with their female counterparts.[@b2-cia-9-1247],[@b3-cia-9-1247] Osteoporotic fractures also cause a substantial financial burden to society and decrease quality of life for patients,[@b4-cia-9-1247],[@b5-cia-9-1247] so should be prevented. The age-related decrease in testosterone is a major risk factor for male osteoporosis.[@b6-cia-9-1247],[@b7-cia-9-1247] Several pharmacologic antiosteoporotic agents are available on the market, including bisphosphonates, teriparatide, and strontium ranelate, but are not free of side effects.[@b8-cia-9-1247] Calcium supplementation with and without vitamin D is commonly prescribed, but has been associated with an increased risk of cardiovascular events.[@b9-cia-9-1247] This has prompted a search for other agents with the potential to prevent osteoporosis.

Tocotrienol is a subset of the vitamin E family, derived from plant oils, and has been shown to have antiosteoporotic effects.[@b10-cia-9-1247],[@b11-cia-9-1247] Previous studies in animal models of osteoporosis have demonstrated that mixtures of tocotrienols can prevent degenerative changes in trabecular bone induced by estrogen deficiency,[@b12-cia-9-1247]--[@b14-cia-9-1247] free radicals,[@b15-cia-9-1247] and nicotine.[@b16-cia-9-1247] Tocotrienols have also been shown to preserve bone mineral density and calcium content in rats with dexamethasone-induced osteoporosis.[@b17-cia-9-1247],[@b18-cia-9-1247] These studies have used palm tocotrienols, which contain a substantial amount of alpha-tocopherol (αTF). Fujita et al have shown that αTF promotes fusion of osteoclasts and increases bone resorption,[@b19-cia-9-1247] which might interfere with the bone-protective effects of a tocotrienol mixture containing αTF. However, previous studies have not used molecular techniques, so the bone-protective mechanism of tocotrienol remains unclear.

Annatto-derived tocotrienol (AnTT) contains a high proportion of δTT and virtually no αTF,[@b20-cia-9-1247] so provides an opportunity to study the antiosteoporotic effects of tocotrienol without the interference of αTF. Abdul-Majeed et al found that osteoporotic changes due to estrogen deficiency were prevented in ovariectomized rats supplemented with AnTT 60 mg/kg for 8 weeks.[@b21-cia-9-1247] We hypothesized that AnTT at this dose would be able to prevent male osteoporosis induced by testosterone deficiency.

In the current study, we evaluated the effects of AnTT on trabecular bone in orchidectomized rats with respect to changes in bone structural indices, remodeling, and gene expression. In addition to previously used bone histomorphometric methods, we used microcomputed tomography (μCT) for more accurate three-dimensional estimation of bone structural parameters. Expression of genes related to bone formation and resorption was quantified to provide a mechanistic overview of how AnTT could prevent degenerative changes in bone. The information generated by this study could be used to determine whether AnTT acts as a preventive agent in male osteoporosis caused by testosterone deficiency. It also serves as a basis for use of AnTT in future clinical trials in humans.

Materials and methods
=====================

Materials
---------

The AnTT used in this study was a generous gift from American River Nutrition (Hadley, MA, USA). It was composed of approximately 90% δTT and 10% γTT, with no αTF. It was diluted in olive oil (Bartolini Emilio, Arrone Terni, Italy) and administered orally at a dose of 60 mg/kg body weight. Olive oil was used for dilution because it contains a low level of vitamin E (51 ppm).[@b22-cia-9-1247] Testosterone enanthate (Jesalis Pharma, Jena, Germany) was diluted with peanut oil (Sime Darby, Subang Jaya, Malaysia) and administered intramuscularly at a dose of 7 mg/kg body weight. Peanut oil was used for dilution because the formulation used contains peanut oil.

Treatment of animals
--------------------

Forty 3-month-old intact Sprague-Dawley rats (250--300 g) were purchased from the Laboratory Animal Research Unit, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia. They were acclimatized at the local vivarium for one week (room temperature, 12-hour light/dark cycle). The rats were housed singly in plastic cages with free access to tap water and standard rat chow (Gold Coin, Port Klang, Malaysia). They were stratified into five groups using random numbers generated by statistical software. Orchidectomy was performed in the orchidectomized, AnTT, and testosterone groups. A sham-operated group underwent similar surgical treatment but their testes were not removed. The baseline group was sacrificed without undergoing any surgical treatment or intervention. The AnTT group received AnTT daily (60 mg/kg body weight, oral gavage) for 8 weeks, while the other groups received an equal volume of the olive oil vehicle. The testosterone group received weekly testosterone enanthate injections (7 mg/kg body weight, intramuscularly) for 8 weeks while the other groups received an equal volume of the peanut oil vehicle. Treatment was initiated a week after orchidectomy. The weight of each rat was monitored weekly using a digital scale (Tanita Model 1,144, Tokyo, Japan) and recorded to the nearest 1 g. At the end of the treatment period, the rats were euthanized using diethyl ether (HmbG Chemicals^®^, Hamburg, Germany), after which their femoral and tibial bones were harvested. After the soft tissue was removed, the bones were either stored in 10% formalin solution for histomorphometric and μCT evaluation, or at −70°C for study of gene expression. The study protocol was reviewed and approved by the animal ethics committee at Universiti Kebangsaan Malaysia (Code FP/FAR/2012/IMA/18-July/445-July-2012-April-2014).

MicroCT analysis
----------------

Trabecular parameters were investigated at the left proximal tibia using a μCT 40 scanner (Scanco Medical, Brüttisellen, Switzerland). A sample was placed in a holder and scanned in an upright position. The volume of interest (200 slices) selected started from 1.5 mm distal to the lowest point of the proximal growth plate and extended towards the distal end of the tibia. Images were acquired at 70 kVp and 114 μA with high resolution. The integration time was 200 msec.

Contouring was performed using a semiautomated method to select the trabecular region. Three-dimensional reconstruction and evaluation were performed using Scanco software (Scanco Medical) to measure the following bone parameters: trabecular bone volume, trabecular number, trabecular separation, trabecular thickness, structural model index, and connectivity density.

Bone processing and histomorphometry
------------------------------------

Fluorochrome labeling was performed using calcein (Sigma-Aldrich, St Louis, MO, USA) 20 mg/kg body weight administered intraperitoneally on days 9 and 2 before the rats were euthanized. Undecalcified left rat femurs were embedded in polymethyl methacrylate (Sigma-Aldrich) and sectioned at a thickness of 9 μm using a microtome (Leica RM2235, Nussloch, German). Sections to be used for evaluation of bone structure were stained using the Von Kossa method, while unstained sections were used for assessment of bone dynamics.

The region assessed was the secondary spongiosa in the metaphyseal region, which is 3--7 mm from the lowest point of the growth plate and 1 mm from the lateral cortex. Structural parameters were investigated by an automated method using an image analyzer (MediaCybernetics Image Pro-Plus, Rockville, MD, USA). Dynamic parameters were investigated using a fluorescence microscope (Nikon Eclipse 80i, Tokyo, Japan) and measured manually using a Weibel grid. The structural parameters measured included trabecular bone volume, thickness, number, and separation. Dynamic parameters measured included single-labeled surface, double-labeled surface, mineralizing rate, mineral apposition rate, and bone formation rate.

Biochemical analysis
--------------------

Blood was collected from the rats prior to euthanasia via the retro-orbital sinus. Serum was extracted immediately after centrifuging the blood at 3,000 rpm for 10 minutes. The serum was stored at −70°C until analysis. Osteocalcin and carboxy-terminal of type 1 collagen crosslinks were measured using an enzyme-linked immunosorbent assay kit (Immunodiagnostic Systems, Tyne and Wear, UK).

Gene expression analysis
------------------------

A sample of trabecular bone was taken from the distal right femur and homogenized in buffer provided by the manufacturer using a high-speed homogenizer (Bead Ruptor 24, Omni, Kennesaw, GA, USA) and steel beads at 4°C. The tissue lysate was incubated at 65°C and centrifuged to precipitate the debris.

mRNA expression was quantified using the QuantiGene Plex 2.0^®^ technique (Panomics/Affymetrix Inc, Santa Clara, CA, USA) according to the manufacturer's instructions. Oligonucleotide probe sets for the genes of interest were designed by the manufacturer. The tissue lysate was pipetted into a 96-well plate preloaded with capture reagent and a probe set. After incubation overnight at 54°C, hybridization with the preamplifier, amplifier, and biotinylated label was carried out. Luminescence was measured using a Luminex^®^ instrument (Bio-Rad, Hercules, CA, USA), and the mean fluorescence intensity specific for each gene (proportional to the mRNA captured by the bead) was generated. Expression of each gene was normalized to the expression of glyceraldehyde 3-phosphate dehydrogenase. The genes of interest are listed in [Table 1](#t1-cia-9-1247){ref-type="table"}.

Statistical analysis
--------------------

Distribution of the data was assessed using the Shapiro--Wilk test and all data were found to be normally distributed. One-way analysis of variance, with either Tukey's or Dunnett's T3 as the post hoc test, was used to detect significant differences in the variables of interest between the study groups. All data are presented as the mean and standard error of the mean. *P*-values \<0.05 were considered to be statistically significant. The statistical analysis was performed using Statistical Package for Social Sciences version 16.0 software (SPSS Inc, Chicago, IL, USA).

Results
=======

Rats in all the treatment groups gained weight throughout the study period. The percent increase in body weight was significantly less in the testosterone group than in the sham and AnTT groups (*P*\<0.05, [Figure 1A](#f1-cia-9-1247){ref-type="fig"}).

Orchidectomy resulted in decreased bone quality, as indicated by a significant reduction in trabecular bone volume, trabecular number, and connectivity density, and a significant increase in trabecular separation in the orchidectomized group when compared with the sham group using μCT at the proximal tibia (*P*\<0.05). Similar structural changes were observed at the distal femur, ie, the orchidectomized group showed significant reductions in trabecular bone volume, number, and thickness, and a significant increase in trabecular separation when compared with the sham group (*P*\<0.05). Treatment with testosterone was able to prevent these degenerative changes completely (*P*\<0.05), and treatment with tocotrienol was able to prevent adverse changes at the distal femur (*P*\<0.05). Structural indices at the proximal tibia showed a trend towards improvement in the AnTT group when compared with the orchidectomized group, but only values for trabecular separation reached statistical significance (*P*\<0.05; [Figure 2](#f2-cia-9-1247){ref-type="fig"} and [Figure 3A--D](#f3-cia-9-1247){ref-type="fig"}).

Dynamic histomorphometric variables (single-labeled surface, double-labeled surface, mineralizing rate, mineral apposition rate, and bone formation rate) were not significantly different between the orchidectomized and sham groups (*P*\>0.05). Treatment with testosterone suppressed bone remodeling, as evidenced by a significant reduction in double-labeled surface and a significant increase in single-labeled surface in the testosterone group as compared with the sham and AnTT groups (*P*\<0.05). Supplementation with tocotrienol increased bone remodeling, as indicated by a significant increase in double-labeled surface and a significant decrease in single-labeled surface (*P*\<0.05; [Figure 3E--I](#f3-cia-9-1247){ref-type="fig"}).

The difference between treatment with testosterone and treatment with AnTT with regard to the bone remodeling process was further supported by the bone turnover marker results. The orchidectomized group showed a marginally higher osteocalcin level when compared with the sham group, but the difference was not statistically significant (*P*\>0.05). Treatment with testosterone significantly suppressed osteocalcin levels in comparison with the orchidectomized group (*P*\<0.05). The tocotrienol-treated group showed higher osteocalcin levels than the orchidectomized group, although the difference was not statistically significant (*P*\>0.05). There was no difference in C-terminal of type 1 collagen crosslink levels between the groups (*P*\>0.05; [Figure 1B and C](#f1-cia-9-1247){ref-type="fig"}).

In general, gene expression was not significantly different between the sham and orchidectomized groups (*P*\>0.05). *RANKL* and *PPARG* gene expression was significantly lower in the testosterone group than in the orchidectomized group (*P*\<0.05). Treatment with tocotrienol significantly increased the expression of several bone formation genes, such as *ALPL*, when compared with the sham and orchidectomized groups (*P*\<0.05), *COL1α1* when compared with the orchidectomized group (*P*\<0.05), and *CTNNB1* when compared with the sham group (*P*\<0.05). Tocotrienol also significantly suppressed expression of *RANKL* and *PPARG* mRNA when compared with the orchidectomized group (*P*\<0.05). Expression of *RUNX-2* and *SPARC* was also higher, albeit not significantly so, in the AnTT group when compared with the sham and orchidectomized groups (*P*\>0.05). There was no significant difference in expression of osteoclast-related genes between the groups with and without AnTT treatment (*P*\>0.05; [Figures 4](#f4-cia-9-1247){ref-type="fig"} and [5](#f5-cia-9-1247){ref-type="fig"}).

Discussion
==========

The present study indicates that osteoporosis induced by testosterone deficiency is characterized by a decrease in bone structural indices, such as trabecular bone volume, number, and thickness, as well as an increase in trabecular separation. These changes subsequently led to increased bone porosity, as evidenced by decreased connectivity density. There were no dramatic differences in indices of bone dynamics or bone remodeling markers between the orchidectomized and sham groups, probably because the increase in remodeling favorable to net bone loss was transient and had slowed down after 2 months. This also explains the lack of overt differences in gene expression profile between the orchidectomized and sham groups.

In the current study, the tocotrienol and testosterone interventions were found to preserve bone health in rats via two distinct mechanisms. Testosterone inhibited both bone formation (as evidenced by a significant decrease in double-labeled surface and serum osteocalcin level) and bone resorption (as evidenced by a significant decrease in RANKL mRNA expression), so bone remodeling was halted. Tocotrienol uncoupled bone remodeling by promoting bone formation (as evidenced by a significant increase in double-labeled surface and expression of bone formation genes), with a negligible impact on bone resorption (as indicated by no significant changes in osteoclast-related gene expression). Differences between AnTT and testosterone with regard to the bone-protective mechanism have a significant clinical impact. We showed that testosterone was more effective than AnTT in preserving trabecular structure at the femur and tibia. However, inhibition of bone remodeling by testosterone could lead to accumulation of microfractures, thereby weakening the bone if not repaired via the normal remodeling process. On the other hand, AnTT activated bone formation but had negligible effects on bone resorption, resulting in a net gain of bone, which counteracted the loss of bone mass due to testosterone deficiency. Since bone remodeling was not suppressed, AnTT would allow repair of microfractures. However, examination of microfractures was outside the scope of the present study.

The use of a δTT-predominant AnTT mixture without any αTF is a novel approach in the prevention of male osteoporosis, so no comparable studies are available. A previous study by Abdul-Majeed et al showed that supplementing ovariectomized female rats with AnTT 60 mg/kg for 8 weeks prevented adverse changes in femoral trabecular bone due to estrogen deficiency, as evidenced by improvements in cellular and static bone parameters.[@b21-cia-9-1247] Bone formation was increased and bone resorption was decreased in the AnTT-treated group in that study,[@b21-cia-9-1247] whereas only bone formation was increased in the present study. This discrepancy might be due to sex differences in the response of bone to treatment with AnTT. Many studies had been performed previously using γTT-predominant palm-derived tocotrienol mixtures containing 20%--30% αTF to investigate the antiosteoporotic effects of tocotrienol.[@b10-cia-9-1247] The majority of these studies found that palm-derived tocotrienols at 60 mg/kg body weight were effective in preventing degenerative changes in structural, dynamic, cellular and static indices of bone in osteoporosis induced by estrogen deficiency,[@b12-cia-9-1247]--[@b14-cia-9-1247] nicotine,[@b16-cia-9-1247] and free radicals.[@b15-cia-9-1247] In a study using normal rats, isomers of tocotrienol were found to have anabolic effects on bone as evaluated by biomechanical strength testing and histomorphometric evaluation.[@b23-cia-9-1247] Hence, the current study showed that AnTT also exerted anabolic effects on bone in male rats with testosterone deficiency.

Very few studies have explored the bone-protective mechanism of tocotrienols, and the antiosteoclastogenic effects of tocotrienols were given more emphasis in the available in vitro studies. In vitro studies by Brooks et al[@b24-cia-9-1247] and Ha et al[@b25-cia-9-1247] demonstrated that tocotrienol isomers were able to decrease the formation and differentiation of osteoclasts from human CD14+ cells and mouse bone marrow macrophages and the resorption activity of osteoclasts. Ha et al further demonstrated that the antiosteoclastogenic effects of αTT could be attributed to disruption of RANKL signaling.[@b25-cia-9-1247] These observations were supported by several in vivo studies, in which eroded surface and osteoclast surface of trabecular bone were reduced in tocotrienol-supplemented female animals.[@b21-cia-9-1247] The present research shows that AnTT supplementation significantly increases the expression of genes related to bone formation (*ALPL, COL1α1*, and *CTNNB1*) but does not have a significant influence on expression of genes related to osteoclasts. Although expression of *RANKL* was decreased in the AnTT group, expression of other genes related to osteoclast function (*ACP5, CTSK*, and *ITGB3*) and signaling (*NFATC1* and *SRC*) was not affected. Further, treatment with AnTT decreased expression of *PPARG*, which is responsible for differentiation of adipocytes, indicating that bone marrow mesenchymal cells were more committed to differentiate into osteoblasts (indicated by marginally higher but not statistically significant *RUNX* expression in the AnTT group) instead of adipocytes. In view of previous evidence regarding the antiosteoclastogenic effects of tocotrienols, we postulate that the dose used in the current study was sufficient to activate genes for bone formation but not those for bone resorption. It is also possible that the effect of the AnTT mixture on bone remodeling was different from that of single tocotrienol isomers and palm-derived tocotrienol mixtures, whereby the AnTT mixture exerted predominantly anabolic but not antiresorptive effects in bone.

There are several advantages to using an αTF-free tocotrienol mixture. A study by Fujita et al showed that αTF stimulated osteoclast fusion and increased bone resorption activity, but other vitamin E isomers did not.[@b19-cia-9-1247] Alpha-TF was also shown to compete with other vitamin E isomers to bind with αTF transport protein, which secretes vitamin E isomers into the circulation,[@b26-cia-9-1247] thus reducing the level of tocotrienol isomers beneficial to bone health. This was supported by intervention studies, in which αTF supplementation decreased circulating levels of other tocopherols and tocotrienols.[@b27-cia-9-1247],[@b28-cia-9-1247] These undesirable characteristics of αTF might interfere with the bone-protective effects of tocotrienols and subsequently reduce their efficacy.[@b29-cia-9-1247]

Several limitations need to be considered in interpreting the results of the present study. The affinity of αTF transport protein for δTT and γTT was very low.[@b26-cia-9-1247] We did not determine the amount of tocotrienol that reached the circulation or bone. However, previous animal studies have shown that supplementation with tocotrienol 60 mg/kg improves bone quality.[@b21-cia-9-1247] Trabecular bone was studied because it is metabolically active and provides a large surface to volume ratio for interaction between soluble factors and bone.[@b30-cia-9-1247] Thus, trabecular bone would show a more rapid response than cortical bone when studying compounds that could affect bone. The antiosteoporotic effects of AnTT could be further explored by varying the dose and treatment duration. The dosage and treatment period in the current study were based on those used in an earlier ovariectomized osteoporosis model.[@b21-cia-9-1247]

This study is novel because the effects of an AnTT mixture with a unique composition of 90% δTT and 10% γTT have never been examined before in osteoporosis induced by testosterone deficiency. Previous studies have used palm-derived tocotrienol mixtures and focused on estrogen-induced osteoporosis and other models. The absence of αTF in the mixture allows the effects of tocotrienols to be studied without undesirable interference. This study characterized the effects of AnTT on gene expression in bone, which has not been done by previous researchers. This allowed a better understanding of the mechanisms underlying the bone-protective action of AnTT. A gene expression study was performed using a multiplex platform that reduced errors due to sample processing, dilution, and amplification. The multiplex platform has been reported to have a lower coefficient of variation when compared with the traditional reverse transcriptase polymerase chain reaction.[@b31-cia-9-1247]

Conclusion
==========

AnTT 60 mg/kg showed promising antiosteoporotic effects in rats with osteoporosis induced by testosterone deficiency. These antiosteoporotic effects are attributed to an increase in bone formation activity brought about by increased expression of genes related to bone formation. AnTT protects bone via a different mechanism when compared with testosterone replacement, which inhibits the bone modeling process. Further research of AnTT should be conducted by varying the dose and treatment duration, when examining the antiosteoporotic effects of AnTT in male osteoporosis induced by testosterone deficiency.
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![Percentage changes in body weight, serum terminal-C type 1 collagen crosslinks, and osteocalcin levels in rats. The bar charts show the percentage change in body weight (**A**), serum terminal-C type 1 collagen crosslinks (**B**), and osteocalcin levels (**C**) before and after treatment. The data are shown as the mean with the standard error of the mean.\
**Notes:** ^b^Significant difference versus the sham group; ^c^significant difference versus the orchidectomized group; ^d^significant difference versus the AnTT group. The statistical significance value is set at *P*\<0.05.\
**Abbreviations:** AnTT, annatto tocotrienol-supplemented group; BL, baseline group; CTX-1, terminal-C type 1 collagen crosslinks; ORX, orchidectomized group; SH, sham-operated group; TE, testosterone enanthate-supplemented group.](cia-9-1247Fig1){#f1-cia-9-1247}

![Bone structural indices in proximal tibia of rats evaluated using μCT. The bar charts (**A**--**F**) show bone structural indices at the proximal tibia evaluated using μCT. The data are shown as the mean and standard error of the mean.\
**Notes:** ^a^Significant difference versus the baseline group; ^b^significant difference versus the sham group; ^c^significant difference versus the orchidectomized group. The statistical significance value is set at *P*\<0.05.\
**Abbreviations:** AnTT, annatto tocotrienol-supplemented group; BL, baseline group; ORX, orchidectomized group; SH, sham-operated group; TE, testosterone enanthate-supplemented group; SMI, Structural model index; Conn.D, connectivity density; BV/TV, bone volume over total volume; Tb. N., trabecular number; Tb. Th., trabecular thickness; Tb. Sp., trabecular separation.](cia-9-1247Fig2){#f2-cia-9-1247}

###### 

Bone structural and dynamic indices at the distal femur in rats evaluated using the bone histomorphometry technique. The bar charts show the bone structural (**A**--**D**) and dynamic (**E**--**I**) indices at the distal femur evaluated using the bone histomorphometry technique. The data are shown as the mean and standard error of the mean.

**Notes:** ^a^Significant difference versus the baseline group; ^b^significant difference versus the sham group; ^c^significant difference versus the orchidectomized group; ^d^significant difference versus the AnTT group. The statistical significance value is set at *P*\<0.05.

**Abbreviations:** AnTT, annatto tocotrienol-supplemented group; BL, baseline group; ORX, orchidectomized group; SH, sham-operated group; TE, testosterone enanthate-supplemented group; BV/TV, bone volume over total volume; Tb.N., trabecular number; Tb. Th., trabecular thickness; Tb. Sp., trabecular separation; dLS, double-labeled surface; sLS, single-labeled surface; MAR, mineral apposition rate; MS, mineralizing surface; BFR, bone formation rate.
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###### 

Relative expression of genes related to osteoblast differentiation/bone formation in rats. The bar charts (**A**--**I**) show the relative expression of genes related to osteoblast/bone formation. The data are shown as the mean with standard error of the mean.

**Notes:** ^b^Significant difference versus the sham group; ^c^significant difference versus the orchidectomized group; ^d^significant difference versus the AnTT group. The statistical significance value is set at *P*\<0.05.

**Abbreviations:** AnTT, annatto tocotrienol-supplemented group; BL, baseline group; ORX, orchidectomized group; SH, sham-operated group; TE, testosterone enanthate-supplemented group; MFI, mean fluorescence intensity.
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![Relative expression of genes related to osteoclastogenesis/osteoclast function/bone resorption and *PPARG* in rats. The bar charts (**A**--**H**) show the relative expression of genes related to osteoclastogenesis/osteoclast function/bone resorption and *PPARG*. The data are shown as the mean and the standard error of the mean.\
**Notes:** ^b^Significant differences versus the sham group; ^c^significant differences versus the orchidectomized group; ^d^significant difference versus the AnTT group. The statistical significance value is set at *P*\<0.05.\
**Abbreviations:** AnTT, annatto tocotrienol-supplemented group; BL, baseline group; ORX, orchidectomized group; SH, sham-operated group; TE, testosterone enanthate-supplemented group; MFI, mean fluorescence intensity.](cia-9-1247Fig5){#f5-cia-9-1247}

###### 

Genes of interest in this study

  Gene                     NCBI accession number   Name
  ------------------------ ----------------------- ----------------------------------------------------------------------------------------------------
  **Osteoblast-related**                           
  *ALPL*                   NM_013059               Alkaline phosphatase
  *BGLAP*                  NM_013414               Osteocalcin or bone gamma-carboxyglutamate (gla) protein
  *COL1A1*                 NM_053304               Collagen, type I, alpha 1
  *CTNNB1*                 NM_053357               Catenin (cadherin associated protein), beta 1
  *IBSP*                   NM_012587               Integrin-binding sialoprotein
  *RUNX2*                  NM_053470               Runt-related transcription factor 2
  *SP7*                    NM_181374               Sp7 transcription factor
  *SPARC*                  NM_012656               Osteonectin or secreted protein, acidic, cysteine-rich
  *OPG/TNFRSF11b*          NM_012870               Osteoprotegerin/tumor necrosis factor receptor superfamily, member 11b
  **Osteoclast-related**                           
  *ACP5*                   NM_019144               Acid phosphatase 5, tartrate resistant
  *CTSK*                   NM_031560               Cathepsin K
  *ITGB3*                  NM_153720               Integrin, beta 3
  *NFATc1*                 XM_001058445            Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1
  *SPP1*                   NM_012881               Osteopontin or secreted phosphoprotein 1 or Bone sialoprotein 1
  *SRC*                    NM_031977               Src v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian)
  *RANKL/TNFSF11*          NM_057149               Receptor activator of nuclear factor kappa-b/tumor necrosis factor (ligand) superfamily, member 11
  **Others**                                       
  *PPARG*                  NM_001145366            Peroxisome proliferator-activated receptor gamma, transcript variant 2
